4DO5

Pharmacological chaperones for human alpha-N-acetylgalactosaminidase

(2012) Proc Natl Acad Sci U S A 109: 17400-17405

• PubMed: 23045655 Search on PubMedSearch on PubMed Central
• DOI: https://doi.org/10.1073/pnas.1203924109
• Primary Citation of Related Structures:  
  4DO4, 4DO5, 4DO6


• PubMed Abstract: 
  

  Schindler/Kanzaki disease is an inherited metabolic disease with no current treatment options. This neurologic disease results from a defect in the lysosomal α-N-acetylgalactosaminidase (α-NAGAL) enzyme. In this report, we show evidence that the iminosugar DGJNAc can inhibit, stabilize, and chaperone human α-NAGAL both in vitro and in vivo. We demonstrate that a related iminosugar DGJ (currently in phase III clinical trials for another metabolic disorder, Fabry disease) can also chaperone human α-NAGAL in Schindler/Kanzaki disease. The 1.4- and 1.5-Å crystal structures of human α-NAGAL complexes reveal the different binding modes of iminosugars compared with glycosides. We show how differences in two functional groups result in >9 kcal/mol of additional binding energy and explain the molecular interactions responsible for the unexpectedly high affinity of the pharmacological chaperones. These results open two avenues for treatment of Schindler/Kanzaki disease and elucidate the atomic basis for pharmacological chaperoning in the entire family of lysosomal storage diseases.

   View More

---

Organizational Affiliation: 

Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, MA 01003, USA.